Blinatumomab prolongs survival after MRD-negative...

Blinatumomab prolongs survival after MRD-negative…

0 Comments

medicine Tuesday, August 6, 2024 Rochester/Minnesota Additional treatment with the BITE antibody blinatumomab can improve the results of consolidation chemotherapy in patients with BCR::ABL1-negative B-precursor ALL who had no minimal residual disease (MRD) after previous